Cell Analysis Market

Cell Analysis Market by Product & Service (Consumables, Instruments), Technique (Flow Cytometry, PCR, Microscopy), Process (Counting, Viability, Proliferation, Interaction, Single-cell Analysis), End User (Pharma, Biotech) - Global Forecast to 2028

Report Code: BT 2358 Jul, 2023, by marketsandmarkets.com

The global cell analysis market in terms of revenue was estimated to be worth $20.2 billion in 2023 and is poised to reach $33.9 billion by 2028, growing at a CAGR of 10.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increase in the preference for cell-bsaed assays along with strong funding for cell-based research is expected to drive the market growth. The conventional methods of toxicity and drug safety assessment (involving animal testing) are expensive, time-consuming, and offer low-throughput. In this regard, modern cell-based assays merge the advantages of cell cultures and animal models to allow researchers to identify problems with lead compounds in early screening, ensuring greater efficiency in the drug discovery and development process.

Attractive Opportunities in the Cell Analysis Market

Cell Analysis Market

To know about the assumptions considered for the study, Request for Free Sample Report

Cell Analysis Market

Cell Analysis Market Dynamics

DRIVER: Growing number of drug discovery activities

Adoption of cell-based screening assays has increased in he drug discovery activities to understand associated complexities. Additionally, advances in cell biology, bioinformatics, molecular biology, genomics, and proteomics have generated large volumes of data, owing to which the use of cell-based assays in the drug development process has gained importance. Similarly, the Human Genome Project has generated a number of targets on which drug screening experiments can be carried out. This rapid expansion in drug targets and drug leads in recent years has accelerated the development of cell-based assays for primary and secondary screening in drug discovery.

RESTRAINT: High cost of instruments and restrictions on reagent use

The introduction of high-throughput screening (HTS) and high-content screening (HCS) technologies in cell analysis has increased their reliability. However, these technologies have also resulted in a significant increase in the cost of instruments. Moreover, the time and cost involved in each HTS process are directly proportional to the target molecule’s complexity; consequently, the higher the complexity, the greater the cost. In biopharmaceutical companies, the overall cost of production of biopharmaceuticals has increased considerably due to the use of these expensive systems.

OPPORTUNITY: Application of novel cell-based assays in cancer research

In the last few decades, the incidence and prevalence of cancer have increased significantly across the globe, and this trend is expected to continue in the coming years. In an effort to reduce cancer incidence and mortality, the demand for novel approaches that offer effective cancer diagnosis and treatment has increased in recent years. In this regard, some recent studies have been published that highlight the importance of cell-based assays in cancer research.

Global Cell Analysis Ecosystem Analysis

The cell analysis industry ecosystem comprises raw material suppliers, service providers, and end users such as pharmaceutical & biotechnology companies, CROs, hospitals, and diagnostic laboratories. Raw material suppliers & product manufacturers offer various supplies & products for different cell analysis processes. Cell analysis companies entered into partnerships with their clients, such as pharmaceutical companies, in order to design a strategy for the design and development of cell analysis products, including assays, reagents, instruments & accessories, and software solutions. This long-term relationship enables partners to develop cell-based research experiments successfully and bring new therapeutic and diagnostic solutions to the market. Also, as partners work together for a long time, the volume of work contracted out can expand, depending on how comfortable both the partners are in taking the partnership forward.

Cell Analysis Market Ecosystem

The software segment of the cell analysis industry is expected to grow at the highest rate during the forecast period

Based on product & service, the global cell analysis market is segmented into reagents & consumables, instruments, accessories, software, and services. The reagents & consumables segment accounted for the largest share of the market in 2022. Prominent companies are providing flow cytometry reagents as directly conjugated products. Companies are introducing high-quality reagents with an enhanced geographic reach contributing to the largest share of the reagents & consumables market. Innovative offerings addressing complex datasets with multiple analytical modalities for effective interpretation is the key contributing factor to the segment’s fastest growth.

The flow cytometry technique dominated the cell analysis industry

Based on technique, the global cell analysis market is segmented into flow cytometry, PCR, cell microarrays, microscopy, spectrophotometry, high-content screening, and other techniques. The flow cytometry segment accounted for the largest market share in 2022. Increase in demand for flow cytometry in single-cell analysis studies to analyze multiple characteristics of the sample at single-cell level is the key driving factor of this segment. Additionally, high-content screening segment has registerd highest growth ratefrom 2023-2028, with high demand for HCS products in cell behavior studies.

The single-cell analysis segment of the cell analysis industry is expected to register the highest CAGR during the forecast period

Based on process, the global cell analysis market is segmented into cell identification, cell viability, cell signaling pathway/signal transduction, cell proliferation, cell counting & quality control, cell interaction, cell structure study, target identification & validation, and single-cell analysis. Cell identification accounted for the largest market share of in 2022. High adoption of cell identification products across industrial applications, including food and healthcare is a key contributing factor to the segment growth. Cell identification is crucial to drug discovery and high adoption of these products have propelled companies to introduce innovative products. On the other hand, single-cell analysis segment is expected to grow at the fastest pace during the forecast period. Single-cell analysis has gained significant traction over the years for assessment of individual cells at multi-parametric level, contributing to the segment growth.

The pharmaceutical & biotechnology companies accounted for the largest share in the cell analysis industry

Based on end user, the cell analysis market is segmented into pharmaceutical & biotechnology companies, hospitals & clinical testing laboratories, academic & research institutes, and other end users. The other end users are inclusive of forensic laboratories, blood banks, CROs, food & beverage manufacturers, and environmental monitoring organizations. The pharmaceutical & biotechnology companies segment accounted for the largest market share in 2022. Frequent adoption of consumables and instruments across different steps in drug discovery & development has led to the dominance of pharmaceutical & biotechnology end users. Additionally, hospitals and clinical testing laboratories segment is anticipated to grow at the fastest pace throughout the forecast period. Adoption of highly complex and specialized assays across this end user segment is expected to support its rapid growth.

North America was the largest regional market for cell analysis industry in 2022.

Geographically, the cell analysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America region is expected to dominate the market through 2021-2028, followed by Europe. The US pharmaceutical industry has witnessed tremendous growth due to the increasing approval of first-in-class drugs by the Food and Drugs Administration (FDA), rising R&D expenditure by pharmaceutical companies, and the establishment of startups focusing on developing promising drugs for rare diseases and neurological conditions. This has propelled cell-based research activities, offering lucrative opportunities for the growth of the market in the US. Asia Pacific market is expected to grow at the fastest pace through 2023 to 2028.

Cell Analysis Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the global cell analysis market include Danaher (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), General Electric (US), Merck KGaA (US), Agilent Technologies (US), Olympus Corporation (Japan), Miltenyi Biotec (US), Bio-Rad Laboratories (US), BioStatus Limited (UK), Fluidigm Corporation (US), NanoCellect Biomedical (US), Cell Biolabs (US), Creative Bioarray (US), Meiji Techno (US), Promega Corporation (US), PerkinElmer (US), Tecan Trading AG (Switzerland), CELLINK (US), QIAGEN (Germany), Corning Incorporated (US), 10x Genomics (US), and Illumina (US).

Scope of the Cell Analysis Industry

Report Metric 

Details 

Market Revenue in 2023

$20.2 billion

Projected Revenue by 2028

$33.9 billion

Revenue Rate

Poised to Grow at a CAGR of 10.9%

Market Driver

Growing number of drug discovery activities

Market Opportunity

Application of novel cell-based assays in cancer research

This report categorizes the cell analysis market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Reagents & Consumables
  • Instruments
  • Accessories
  • Software
  • Service

By Technique

  • Flow Cytometry
  • PCR
  • Cell Microarrays
  • Microscopy
  • Spectrophotometry
  • High Content Screening
  • Other Techniques

By Process

  • Cell Identification
  • Cell Viability
  • Cell Signaling Pathways/Signal Transduction
  • Cell Proliferation
  • Cell Counting and Quality Control
  • Cell Interaction
  • Cell Structure Study
  • Target Identification and Validation
  • Single-Cell Analysis

By End User

  • Pharmaceutical & Biotechnology Companies
  • Hospitals and Clinical Testing Laboratories
  • Academic and Research Institutes
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments of Cell Analysis Industry

  • In 2023, Becton, Dickinson and Company (US) launched a Spectral Cell Sorter that is coupled with high-speed cell imaging. this product combines real-time imaging technology with spectral flow cytometry.
  • In 2020, Miltenyi Biotec (Germany) launched MACS GMP Tyto Cartridge, a GMP-compliant cell sorter..
  • In 2020, Bio-Rad Laboratories, Inc. (US) acquired Celsee, Inc., a provider of instruments and consumables for the isolation, detection, and analysis of single cells. This acquisition expanded the company’s product offerings in the flow cytometry market..

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 31)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 SEGMENTS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 36)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 CELL ANALYSIS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE)
          FIGURE 4 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC: REVENUE SHARE ANALYSIS, 2022
          FIGURE 5 AVERAGE MARKET SIZE ESTIMATION (2022)
    2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 
          FIGURE 6 CELL ANALYSIS INDUSTRY: CAGR PROJECTIONS (2023–2028)
          FIGURE 7 MARKET: ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
    2.4 DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 INSIGHTS FROM PRIMARIES 
          FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
    2.6 RESEARCH ASSUMPTIONS 
    2.7 RISK ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 46)
    FIGURE 10 CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 CELL ANALYSIS INDUSTRY, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET: GEOGRAPHICAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 CELL ANALYSIS MARKET OVERVIEW 
          FIGURE 15 INCREASING FUNDING FOR CELL-BASED RESEARCH TO DRIVE MARKET
    4.2 NORTH AMERICA: MARKET SHARE, BY PRODUCT & SERVICE (2022) 
          FIGURE 16 REAGENTS & CONSUMABLES SEGMENT HELD LARGEST MARKET SHARE IN 2022
    4.3 NORTH AMERICA: MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION) 
          FIGURE 17 FLOW CYTOMETRY SEGMENT TO DOMINATE NORTH AMERICAN MARKET IN 2028
 
5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 18 CELL ANALYSIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 1 CELL ANALYSIS INDUSTRY: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Growing preference for cell-based assays in drug discovery
                    5.2.1.2 Increasing funding for cell-based research
                                TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2019–2021 (USD MILLION)
                    5.2.1.3 Rising number of drug discovery activities
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of instruments and restrictions on reagent use
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth potential of single-cell sequencing
                    5.2.3.2 Application scope of novel cell-based assays in cancer research
           5.2.4 CHALLENGES
                    5.2.4.1 Standardization of protocols and data integration & quality control for developing cell therapies
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 3 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF BUYERS
           5.3.4 BARGAINING POWER OF SUPPLIERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 19 MARKET: VALUE CHAIN ANALYSIS
    5.5 ECOSYSTEM ANALYSIS 
          FIGURE 20 MARKET: ECOSYSTEM ANALYSIS
    5.6 REGULATORY ANALYSIS (FLOW CYTOMETRY-BASED CELL ANALYSIS) 
           5.6.1 STRINGENT FDA REQUIREMENTS
           5.6.2 STRINGENT ANALYTE-SPECIFIC REAGENT RULE
           5.6.3 LACK OF WELL-DEFINED VALIDATION PROTOCOLS FOR CELL-BASED ASSAYS
           5.6.4 ABSENCE OF ESTABLISHED LABORATORY-DEVELOPED TEST GUIDELINES ON CELL-BASED FLUORESCENCE ASSAYS
           5.6.5 GREATER GLOBAL RECOGNITION FOR IVD CE MARK APPROVALS
           5.6.6 US REIMBURSEMENT SCENARIO
    5.7 TECHNOLOGY ANALYSIS 
          FIGURE 21 TECHNOLOGY ANALYSIS: MARKET
    5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
    5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 22 MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
           5.9.2 MARKET: BUYING CRITERIA
                    FIGURE 23 KEY BUYING CRITERIA OF CELL ANALYSIS PRODUCTS
    5.10 KEY CONFERENCES AND EVENTS, 2023–2024 
           TABLE 4 CELL ANALYSIS CONFERENCES (2023–2024)
    5.11 PRICING ANALYSIS 
           5.11.1 AVERAGE SELLING PRICES OF CELL ANALYSIS PRODUCTS & SERVICES
                     TABLE 5 AVERAGE SELLING PRICES OF CELL ANALYSIS PRODUCTS & SERVICES (TOP 5 KEY PLAYERS)*
           5.11.2 AVERAGE SELLING PRICE TREND
 
6 CELL ANALYSIS MARKET, BY PRODUCT & SERVICE (Page No. - 71)
    6.1 INTRODUCTION 
          TABLE 6 CELL ANALYSIS INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 REAGENTS & CONSUMABLES 
           6.2.1 DEVELOPMENT OF NOVEL CELL ANALYSIS KITS & REAGENTS FOR FLOW CYTOMETRY TO BOOST GROWTH
                    TABLE 7 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 8 NORTH AMERICA: MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 9 EUROPE: MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 10 ASIA PACIFIC: MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 INNOVATIONS IN CELL ANALYSIS INSTRUMENTS FOR DRUG DISCOVERY TO DRIVE MARKET
                    TABLE 11 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 12 NORTH AMERICA: MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 13 EUROPE: MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 14 ASIA PACIFIC: MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 ACCESSORIES 
           6.4.1 USE OF ACCESSORIES TO CUSTOMIZE FLOW CYTOMETRY INSTRUMENTS TO BOOST SEGMENT GROWTH
                    TABLE 15 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 16 NORTH AMERICA: MARKET FOR ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 17 EUROPE: MARKET FOR ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 18 ASIA PACIFIC: MARKET FOR ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION)
    6.5 SOFTWARE 
           6.5.1 EXPANDING POOL OF KEY PLAYERS INTRODUCING UNIQUE DATA INTERPRETATION SOFTWARE TO DRIVE SEGMENT
                    TABLE 19 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 20 NORTH AMERICA: MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 21 EUROPE: MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 22 ASIA PACIFIC: MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION)
    6.6 SERVICES 
           6.6.1 WORKFLOW CONTINUITY AND HIGH-PERFORMANCE ATTRIBUTES TO BOOST DEMAND FOR REMOTE SERVICES
                    TABLE 23 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 24 NORTH AMERICA: MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 25 EUROPE: MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 ASIA PACIFIC: MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 CELL ANALYSIS MARKET, BY TECHNIQUE (Page No. - 86)
    7.1 INTRODUCTION 
         TABLE 27 CELL ANALYSIS INDUSTRY, BY TECHNIQUE, 2021–2028 (USD MILLION)
    7.2 FLOW CYTOMETRY 
           7.2.1 ABILITY TO PERFORM MULTIPLE MEASUREMENTS ON SINGLE CELLS TO DRIVE SEGMENT
                    TABLE 28 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 29 NORTH AMERICA: MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 30 EUROPE: MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 31 ASIA PACIFIC: MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 PCR 
           7.3.1 EFFECTIVE MEASUREMENT AND RARE SEQUENCE MONITORING BENEFITS TO DRIVE DIGITAL PCR DEMAND
                    TABLE 32 MARKET FOR PCR, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 33 NORTH AMERICA: MARKET FOR PCR, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 34 EUROPE: MARKET FOR PCR, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 35 ASIA PACIFIC: MARKET FOR PCR, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 CELL MICROARRAYS 
           7.4.1 HIGH EXPERIMENTAL THROUGHPUT OF CELL MICROARRAYS OVER TRADITIONAL METHODS TO DRIVE SEGMENT
                    TABLE 36 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 37 NORTH AMERICA: MARKET FOR CELL MICROARRAYS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 38 EUROPE: MARKET FOR CELL MICROARRAYS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 39 ASIA PACIFIC: MARKET FOR CELL MICROARRAYS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 MICROSCOPY 
           7.5.1 RISING INCIDENCE OF CANCER AND GROWING INVESTMENTS IN CELL BIOLOGY TO DRIVE SEGMENT
                    TABLE 40 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 41 NORTH AMERICA: MARKET FOR MICROSCOPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 42 EUROPE: MARKET FOR MICROSCOPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 43 ASIA PACIFIC: MARKET FOR MICROSCOPY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.6 SPECTROPHOTOMETRY 
           7.6.1 HIGH DEMAND FOR SPECTROPHOTOMETERS IN RESEARCH SETTINGS TO SUPPORT MARKET GROWTH
                    TABLE 44 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 45 NORTH AMERICA: MARKET FOR SPECTROPHOTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 46 EUROPE: MARKET FOR SPECTROPHOTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 47 ASIA PACIFIC: MARKET FOR SPECTROPHOTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.7 HIGH-CONTENT SCREENING 
           7.7.1 HIGH DEMAND FOR HCS IN DRUG DISCOVERY TO SUPPORT SEGMENT GROWTH
                    TABLE 48 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 49 NORTH AMERICA: MARKET FOR HIGH-CONTENT SCREENING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 EUROPE: MARKET FOR HIGH-CONTENT SCREENING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 51 ASIA PACIFIC: MARKET FOR HIGH-CONTENT SCREENING, BY COUNTRY, 2021–2028 (USD MILLION)
    7.8 OTHER TECHNIQUES 
          TABLE 52 MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 53 NORTH AMERICA: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 54 EUROPE: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 55 ASIA PACIFIC: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 CELL ANALYSIS MARKET, BY PROCESS (Page No. - 106)
    8.1 INTRODUCTION 
          TABLE 56 CELL ANALYSIS INDUSTRY, BY PROCESS, 2021–2028 (USD MILLION)
    8.2 CELL IDENTIFICATION 
           8.2.1 INCREASING RESEARCH ACTIVITIES TO PROPEL SEGMENT GROWTH
                    TABLE 57 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 58 NORTH AMERICA: MARKET FOR CELL IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 59 EUROPE: MARKET FOR CELL IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 60 ASIA PACIFIC: MARKET FOR CELL IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 CELL VIABILITY 
           8.3.1 USE OF CELL VIABILITY PROCESS TO CORRELATE CELL BEHAVIOR TO CELL NUMBERS
                    TABLE 61 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 62 NORTH AMERICA: MARKET FOR CELL VIABILITY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 EUROPE: MARKET FOR CELL VIABILITY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: MARKET FOR CELL VIABILITY, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 CELL SIGNALING PATHWAY/SIGNAL TRANSDUCTION 
           8.4.1 HIGH DEMAND FOR TOXICITY TESTING IN DRUG DEVELOPMENT TO DRIVE MARKET
                    TABLE 65 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 66 NORTH AMERICA: MARKET FOR CELL SIGNALING PATHWAY/SIGNAL TRANSDUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 EUROPE: MARKET FOR CELL SIGNALING PATHWAY/SIGNAL TRANSDUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 ASIA PACIFIC: MARKET FOR CELL SIGNALING PATHWAY/SIGNAL TRANSDUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
    8.5 CELL PROLIFERATION 
           8.5.1 MEASUREMENT OF CELL PROLIFERATION BASED ON AVERAGE DNA CONTENT TO DRIVE SEGMENT
                    TABLE 69 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 70 NORTH AMERICA: MARKET FOR CELL PROLIFERATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 71 EUROPE: MARKET FOR CELL PROLIFERATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 72 ASIA PACIFIC: MARKET FOR CELL PROLIFERATION, BY COUNTRY, 2021–2028 (USD MILLION)
    8.6 CELL COUNTING AND QUALITY CONTROL 
           8.6.1 USE OF FLOW CYTOMETRY IN CELL COUNTING TO ENABLE EASY CELL DIFFERENTIATION VIA SCATTERING OR STAINING
                    TABLE 73 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 74 NORTH AMERICA: MARKET FOR CELL COUNTING AND QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 75 EUROPE: MARKET FOR CELL COUNTING AND QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 76 ASIA PACIFIC: MARKET FOR CELL COUNTING AND QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
    8.7 CELL INTERACTION 
           8.7.1 ADVANCEMENT IN CELL-CELL INTERACTIONS/COMMUNICATIONS TO BOOST MARKET GROWTH
                    TABLE 77 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 78 NORTH AMERICA: MARKET FOR CELL INTERACTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 79 EUROPE: MARKET FOR CELL INTERACTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 80 ASIA PACIFIC: MARKET FOR CELL INTERACTION, BY COUNTRY, 2021–2028 (USD MILLION)
    8.8 CELL STRUCTURE STUDY 
           8.8.1 ADVANCEMENTS IN CELLULAR IMAGING TO SUPPORT MARKET GROWTH
                    TABLE 81 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 82 NORTH AMERICA: MARKET FOR CELL STRUCTURE STUDY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 83 EUROPE: MARKET FOR CELL STRUCTURE STUDY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 84 ASIA PACIFIC: MARKET FOR CELL STRUCTURE STUDY, BY COUNTRY, 2021–2028 (USD MILLION)
    8.9 TARGET IDENTIFICATION AND VALIDATION 
           8.9.1 ADOPTION OF HIGH-CONTENT SCREENING IN TARGET IDENTIFICATION TO DRIVE MARKET
                    TABLE 85 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 86 NORTH AMERICA: MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 87 EUROPE: MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 88 ASIA PACIFIC: MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION)
    8.1 SINGLE-CELL ANALYSIS 
           8.10.1 EXPANDING APPLICATIONS OF SINGLE-CELL ANALYSIS IN CLINICAL RESEARCH TO PROPEL SEGMENT GROWTH
                    TABLE 89 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 90 NORTH AMERICA: MARKET FOR SINGLE-CELL ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 91 EUROPE: MARKET FOR SINGLE-CELL ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 92 ASIA PACIFIC: MARKET FOR SINGLE-CELL ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 CELL ANALYSIS MARKET, BY END USER (Page No. - 131)
    9.1 INTRODUCTION 
          TABLE 93 CELL ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 
           9.2.1 HIGH DEMAND FOR CELL-BASED RESEARCH IN DRUG DISCOVERY & DEVELOPMENT TO DRIVE SEGMENT
                    TABLE MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 95 NORTH AMERICA: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 96 EUROPE: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 97 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 HOSPITALS AND CLINICAL TESTING LABORATORIES 
           9.3.1 ADOPTION OF ADVANCED TECHNOLOGIES TO SUPPORT MARKET GROWTH
                    TABLE 98 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 99 NORTH AMERICA: MARKET FOR HOSPITALS AND CLINICAL TESTING LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 100 EUROPE: MARKET FOR HOSPITALS AND CLINICAL TESTING LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 101 ASIA PACIFIC: MARKET FOR HOSPITALS AND CLINICAL TESTING LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 ACADEMIC AND RESEARCH INSTITUTES 
           9.4.1 GROWING NUMBER OF RESEARCH PROJECTS THROUGH INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET
                    TABLE 102 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 103 NORTH AMERICA: MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 104 EUROPE: MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 105 ASIA PACIFIC: MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.5 OTHER END USERS 
          TABLE 106 MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 107 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 108 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 109 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 CELL ANALYSIS MARKET, BY REGION (Page No. - 143)
     10.1 INTRODUCTION 
             TABLE 110 CELL ANALYSIS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 24 NORTH AMERICA: CELL ANALYSIS MARKET SNAPSHOT
             TABLE 111 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 112 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 113 NORTH AMERICA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
             TABLE 114 NORTH AMERICA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 115 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Rising prevalence of cancer to drive cell analysis demand in US
                                      TABLE 116 US: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 117 US: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 118 US: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 119 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Increasing government initiatives targeted toward stem cell research to drive market
                                      TABLE 120 CANADA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 121 CANADA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 122 CANADA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 123 CANADA: CELL ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             TABLE 124 EUROPE: CELL ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 125 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 126 EUROPE: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
             TABLE 127 EUROPE: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 128 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Strong R&D infrastructure, training, and awareness programs to drive market in Germany
                                      TABLE 129 GERMANY: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 130 GERMANY: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 131 GERMANY: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 132 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 FRANCE
                        10.3.2.1 Presence of large biotechnology industry to boost market growth
                                      TABLE 133 FRANCE: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 134 FRANCE: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 135 FRANCE: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 136 FRANCE: CELL ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Growing acceptance of flow cytometry products for clinical diagnostics to drive market
                                      TABLE 137 UK: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 138 UK: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 139 UK: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 140 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Increasing research activities and conferences to support market growth
                                      TABLE 141 ITALY: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 142 ITALY: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 143 ITALY: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 144 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Strong focus on cancer diagnosis to boost flow cytometry product usage in Spain
                                      TABLE 145 SPAIN: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 146 SPAIN: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 147 SPAIN: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 148 SPAIN: CELL ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 149 REST OF EUROPE: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 150 REST OF EUROPE: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                        TABLE 151 REST OF EUROPE: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 152 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 25 ASIA PACIFIC: CELL ANALYSIS MARKET SNAPSHOT
             TABLE 153 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 154 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 155 ASIA PACIFIC: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
             TABLE 156 ASIA PACIFIC: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 157 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Easy access to technologically advanced cell analysis products to favor market growth
                                      TABLE 158 JAPAN: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 159 JAPAN: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 160 JAPAN: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 161 JAPAN: CELL ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Strategic partnerships in cell therapy sector to support market growth
                                      TABLE 162 CHINA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 163 CHINA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 164 CHINA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 165 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Government initiatives to drive market in India
                                      TABLE 166 INDIA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 167 INDIA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                                      TABLE 168 INDIA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 169 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                        TABLE 170 REST OF ASIA PACIFIC: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 171 REST OF ASIA PACIFIC: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                        TABLE 172 REST OF ASIA PACIFIC: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 173 REST OF ASIA PACIFIC: CELL ANALYSIS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 GROWING PARTICIPATION OF ACADEMIC INSTITUTES IN RESEARCH TO ACCELERATE MARKET GROWTH
                        TABLE 174 LATIN AMERICA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 175 LATIN AMERICA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                        TABLE 176 LATIN AMERICA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 177 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 GROWING RESEARCH ACTIVITIES TO FUEL DEMAND FOR CELL ANALYSIS PRODUCTS
                        TABLE 178 MIDDLE EAST & AFRICA: CELL ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 179 MIDDLE EAST & AFRICA: MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
                        TABLE 180 MIDDLE EAST & AFRICA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 181 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 192)
     11.1 INTRODUCTION 
     11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 
             FIGURE 26 CELL ANALYSIS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 MARKET SHARE ANALYSIS 
             FIGURE 27 CELL ANALYSIS INDUSTRY SHARE ANALYSIS (2022)
     11.4 REVENUE SHARE ANALYSIS (TOP 7 MARKET PLAYERS) 
             FIGURE 28 REVENUE ANALYSIS FOR KEY COMPANIES, 2021–2022
     11.5 COMPANY EVALUATION QUADRANT 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 29 CELL ANALYSIS INDUSTRY: COMPANY EVALUATION MATRIX, 2022
     11.6 COMPETITIVE LEADERSHIP MAPPING FOR EMERGING COMPANIES/SMES/START-UPS (2022) 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 30 CELL ANALYSIS INDUSTRY: COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS, 2022
     11.7 COMPETITIVE SCENARIO AND TRENDS 
             11.7.1 PRODUCT LAUNCHES
                        TABLE 182 CELL ANALYSIS INDUSTRY: PRODUCT LAUNCHES
             11.7.2 DEALS
                        TABLE 183 CELL ANALYSIS INDUSTRY: DEALS
 
12 COMPANY PROFILES (Page No. - 203)
     12.1 KEY COMPANIES 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             12.1.1 THERMO FISHER SCIENTIFIC INC.
                        TABLE 184 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 31 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
                        TABLE 185 THERMO FISHER SCIENTIFIC INC.: PRODUCT OFFERINGS
                        TABLE 186 THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES
                        TABLE 187 THERMO FISHER SCIENTIFIC INC.: DEALS
             12.1.2 DANAHER
                        TABLE 188 DANAHER: COMPANY OVERVIEW
                        FIGURE 32 DANAHER: COMPANY SNAPSHOT (2022)
                        TABLE 189 DANAHER: PRODUCT OFFERINGS
                        TABLE 190 DANAHER: DEALS
                        TABLE 191 DANAHER: OTHER DEVELOPMENTS
             12.1.3 BECTON, DICKINSON AND COMPANY (BD)
                        TABLE 192 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
                        FIGURE 33 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2022)
                        TABLE 193 BECTON, DICKINSON AND COMPANY (BD): PRODUCT OFFERINGS
                        TABLE 194 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES
             12.1.4 GENERAL ELECTRIC
                        TABLE 195 GENERAL ELECTRIC: COMPANY OVERVIEW
                        FIGURE 34 GENERAL ELECTRIC: COMPANY SNAPSHOT (2022)
                        TABLE 196 GENERAL ELECTRIC: PRODUCT OFFERINGS
             12.1.5 MERCK KGAA
                        TABLE 197 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2022)
                        TABLE 198 MERCK KGAA: PRODUCT OFFERINGS
             12.1.6 AGILENT TECHNOLOGIES, INC.
                        TABLE 199 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
                        FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 200 AGILENT TECHNOLOGIES, INC.: PRODUCT OFFERINGS
                        TABLE 201 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES
             12.1.7 BIO-RAD LABORATORIES, INC.
                        TABLE 202 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
                        FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 203 BIO-RAD LABORATORIES, INC.: PRODUCT OFFERINGS
                        TABLE 204 BIO-RAD LABORATORIES, INC.: DEALS
             12.1.8 STANDARD BIOTOOLS
                        TABLE 205 STANDARD BIOTOOLS: COMPANY OVERVIEW
                        FIGURE 38 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2022)
                        TABLE 206 STANDARD BIOTOOLS: PRODUCT OFFERINGS
             12.1.9 MILTENYI BIOTEC
                        TABLE 207 MILTENYI BIOTEC: COMPANY OVERVIEW
                        TABLE 208 MILTENYI BIOTEC: PRODUCT OFFERINGS
                        TABLE 209 MILTENYI BIOTEC: PRODUCT LAUNCHES
             12.1.10 OLYMPUS CORPORATION
                        TABLE 210 OLYMPUS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 39 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2022)
                        TABLE 211 OLYMPUS CORPORATION: PRODUCT OFFERINGS
             12.1.11 BIOSTATUS LIMITED
                        TABLE 212 BIOSTATUS LIMITED: COMPANY OVERVIEW
                        TABLE 213 BIOSTATUS LIMITED: PRODUCT OFFERINGS
             12.1.12 NANOCELLECT BIOMEDICAL
                        TABLE 214 NANOCELLECT BIOMEDICAL: BUSINESS OVERVIEW
                        TABLE 215 NANOCELLECT BIOMEDICAL: PRODUCT OFFERINGS
                        TABLE 216 NANOCELLECT BIOMEDICAL: DEALS
                        TABLE 217 NANOCELLECT BIOMEDICAL: PRODUCT LAUNCHES
             12.1.13 CELL BIOLABS, INC.
                        TABLE 218 CELL BIOLABS, INC.: COMPANY OVERVIEW
                        TABLE 219 CELL BIOLABS, INC.: PRODUCT OFFERINGS
             12.1.14 CREATIVE BIOARRAY
                        TABLE 220 CREATIVE BIOARRAY: COMPANY OVERVIEW
                        TABLE 221 CREATIVE BIOARRAY: SERVICE OFFERINGS
             12.1.15 MEIJI TECHNO
                        TABLE 222 MEIJI TECHNO: COMPANY OVERVIEW
                        TABLE 223 MEIJI TECHNO: PRODUCT OFFERINGS
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS 
             12.2.1 PROMEGA CORPORATION
                        TABLE 224 PROMEGA CORPORATION: COMPANY OVERVIEW
             12.2.2 PERKINELMER U.S. LLC
                        TABLE 225 PERKINELMER: COMPANY OVERVIEW
             12.2.3 TECAN TRADING AG
                        TABLE 226 TECAN TRADING AG: COMPANY OVERVIEW
             12.2.4 CARL ZEISS AG
                        TABLE 227 CARL ZEISS AG: COMPANY OVERVIEW
             12.2.5 SYSMEX
                        TABLE 228 SYSMEX: COMPANY OVERVIEW
             12.2.6 CELLINK
                        TABLE 229 CELLINK: COMPANY OVERVIEW
             12.2.7 QIAGEN
                        TABLE 230 QIAGEN: COMPANY OVERVIEW
             12.2.8 ILLUMINA, INC.
                        TABLE 231 ILLUMINA, INC.: COMPANY OVERVIEW
             12.2.9 CORNING INCORPORATED
                        TABLE 232 CORNING INCORPORATED: COMPANY OVERVIEW
             12.2.10 10X GENOMICS
                        TABLE 233 10X GENOMICS: COMPANY OVERVIEW
 
13 APPENDIX (Page No. - 244)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 AVAILABLE CUSTOMIZATIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the cell analysis market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell analysis market. The secondary sources used for this study include World Health Organization (WHO), Organisation for Economic Co-operation and Development (OECD), International Society for Advancement of Cytometry (ISAC), International Society for Stem Cell Research (ISSCR), International Agency for Research on Cancer (IARC), Centers for Disease Control and Prevention (CDC), Society for Laboratory Automation and Screening (SLAS), Centers for Medicare & Medicaid Services (CMS), National Cancer Institute (NCI), European Commission (EC), American Society for Cell Biology (ASCB), European Society for Toxicology In Vitro (ESTIV), European Federation of Pharmaceutical Industries and Associations (EFPIA), Japan Society for Cell Biology (JSCB), Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Indian Society of Cell Biology (ISCB), Food and Drug Administration (FDA), Society of Biomolecular Imaging and Informatics (SBI2), Annual Reports, SEC Filings, Investor Presentations, Press Releases, Conferences, Journals, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Cell Analysis Market Size, and Share

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue. As of 2021, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell analysis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the cell analysis business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Cell Analysis Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Cell analysis is a technique used to study groups of cells and individual cells based on multiple parameters. It is used to measure cell properties such as size, shape, presence of specific proteins, proliferation, growth, morphology, porosity, and complexity.

Cell analysis products are used in various processes, which include cell identification, cell viability, cell proliferation, cell structure study, cell signaling pathway/signal transduction, cell counting & quality control, target identification & validation, cell interaction, and single-cell analysis. These processes are carried out by various end users such as hospitals & clinical testing laboratories, academic and research institutes, pharmaceutical & biotechnology companies, and other end users (CROs, cell culture collection repositories, food & beverage manufacturers, environmental monitoring organizations, forensic laboratories, and blood banks).

Key Stakeholders

  • Pharmaceutical and biopharmaceutical companies
  • Manufacturers of cell analysis equipment
  • Contract research organizations (CROs)
  • Life science research institutes
  • Venture capitalists
  • Research & consulting firms

Report Objectives

  • To define, describe, and forecast the global cell analysis market based on the product & service, technique, process, end user and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall cell analysis market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the cell analysis market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 2358
Published ON
Jul, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cell Analysis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback